Envista Holdings Corporation — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. Envista sells dental implants, orthodontic products, diagnostic equipment, consumables and related services through two segments, serving customers in more than 130 countries.
Financial performance
| Metric | 2023 | 2022 |
|---|---|---|
| Sales | $2,566.5 million | $2,569.1 million |
| Core sales growth (non-GAAP) | (0.4)% | 4.1% |
| Gross profit / margin | $1,440.5 million / 56.1% | $1,474.8 million / 57.4% |
| Operating profit / margin | $31.5 million / 1.2% | $319.2 million / 12.4% |
| Net income (loss) from continuing operations | $(100.2) million | $238.0 million |
| Diluted earnings (loss) per share | $(0.60) | $1.34 from continuing operations |
| Operating cash flow | $275.7 million | $182.7 million |
| Cash and cash equivalents at year-end | $940.0 million | $606.9 million |
| Total debt at year-end | $1,513.4 million | $1,380.7 million |
- Sales and margins: Reported sales were nearly flat, while core sales declined. Volume added 0.7 percentage points to sales growth, but lower pricing reduced it by 1.1 points. Gross margin fell primarily on product mix, pricing and foreign-exchange-related costs.
- Impairments and earnings: 2023 operating profit included $258.3 million of goodwill and intangible-asset impairment charges: $212.3 million for goodwill and $46.0 million for trade names. These charges were non-cash. The effective tax rate was (82.5)%, affected by nondeductible impairment and debt-exchange costs and a valuation allowance on certain U.S. interest carryforwards.
- Cash flow and investment: Operating cash flow increased by $93.0 million year over year. Capital expenditures were $58.2 million; operating cash flow less those additions was approximately $217.5 million. Investing cash outflow was $62.4 million, compared with $657.3 million in 2022, which included acquisition spending.
- Liquidity and debt: The company reported $940.0 million of cash and no revolver borrowings at year-end; $678.4 million of cash was held outside the U.S. Its revolving facility had $750.0 million of available capacity, and it reported compliance with debt covenants. Debt includes variable-rate term loans and convertible notes; the 2025 notes, with $115.3 million carrying value, were classified as current.
Material changes versus 2022
- Specialty Products & Technologies sales rose 2.7% to $1,642.4 million, but segment operating profit declined to $232.1 million from $268.6 million; margin fell to 14.1% from 16.8%.
- Equipment & Consumables sales fell 4.8% to $924.1 million, and segment operating profit declined to $156.3 million from $172.4 million; margin fell to 16.9% from 17.8%.
- North America demand was weaker, partly offset by stronger demand in Europe. Specialty Products & Technologies benefited from growth in Europe and China; its pricing was also affected in part by China’s volume-based procurement program.
- Envista issued $500.2 million of 1.75% convertible notes due 2028 and exchanged $401.2 million principal amount of 2025 notes for approximately $403.0 million in cash and 8.4 million shares. The exchange generated a $28.5 million non-cash inducement charge. Interest expense rose to $63.4 million from $38.4 million.
- Cash increased, while total debt rose. The company’s 2023 loss contrasts with 2022 income, principally reflecting the impairment charges, higher interest expense and debt-exchange costs.
Outlook, commentary and risks
- No quantified 2024 revenue or earnings guidance is provided in the supplied filing text. Management describes ongoing investment in implants, orthodontics, digital workflows, emerging markets and clinical education, alongside cost reduction and productivity initiatives.
- Management cites dental-market growth drivers including aging populations, underpenetrated procedures, digital adoption, cosmetic dentistry and growth of dental service organizations. These are strategic expectations, not guaranteed outcomes.
- Goodwill and indefinite-lived intangible assets totaled approximately $3.7 billion at year-end. Three of eight reporting units were impaired; management’s sensitivity analysis indicated that a hypothetical 10% further decline in fair values could produce approximately $251 million of additional goodwill impairment in those impaired units. A 10% decline for the two impaired trade names could add approximately $30 million of impairment.
- Other key risks include economic weakness and discretionary dental demand, pricing pressure and China procurement policies, foreign exchange, variable interest rates, distributor concentration, supply constraints, product and regulatory compliance, cybersecurity, and integration or execution of restructuring and growth investments. Henry Schein represented approximately 10% of 2023 sales.
- Legal matters: the company had accrued $38.0 million for certain legal contingencies at year-end. It stated that the ultimate outcome of proceedings, net of accruals, was not expected to materially adversely affect financial position, while warning that developments could materially affect results or cash flows in a period.
- The filing notes several executive departures over the prior year, including the CFO, but says these had not materially affected results to date. The financial statements received an unqualified audit opinion; management and the auditor reported effective internal control over financial reporting.
Investor verification priorities
- Assess whether 2023’s segment-level sales and margin trends stabilized, especially the decline in Equipment & Consumables and weaker North American demand.
- Review the assumptions behind the impairment tests and the potential for further charges if forecasts, discount rates or market conditions deteriorate.
- Check debt maturities, variable-rate exposure, convertible-note conversion and cash-settlement obligations, and the availability of cash held overseas.
- Track execution and costs of restructuring and planned growth investments, as well as whether pricing and productivity gains can restore margins.
- Monitor Henry Schein and other distribution-channel relationships, China pricing policy, legal contingency developments and management succession.